Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oncological Outcomes of Recurrence Patterns After BCG in NMIBC
NCT04319263Completed
- Sponsor
- Mansoura University
- Start
- Mar 2020
- Primary completion
- Mar 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Single-arm trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Mansoura University. Primary endpoints: one year Recurrence rate at 1 year and one year progression rate at 1 year. Started Mar 2020; status: completed.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04319263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319263.